PURPOSE: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. METHODS: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34+ progenitor cells. RESULTS: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-gamma-producing CD8+ T cells could be found in two other patients during treatment. CONCLUSIONS: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.
PURPOSE: Immunotherapy using either dendritic cells (DCs) or expanded cytotoxic T cells (CTLs) has received increased interest in the treatment of specific malignancies including metastatic breast cancer (MBC). DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated. METHODS: We enrolled ten patients with MBC that had received prior chemotherapy for the treatment of metastatic disease on a phase I/II trial designed to test the safety and feasibility of administering ex vivo expanded DCs from CD34+ progenitor cells. RESULTS: Using a cocktail of multiple different cytokines, we could expand DCs 19-fold compared to the initial CD34-selected product, which allowed the administration of as many as six vaccine treatments per patient. Patients received three to six injections i.v. of DCs pulsed with either the wild type GP2 epitope from the HER-2/neu protein or an altered peptide ligand, isoleucine to leucine (I2L). Toxicity was mild, with no patients demonstrating grade III toxicity during the treatment. Two patients with subcutaneous disease had a partial response to therapy, while IFN-gamma-producing CD8+ T cells could be found in two other patients during treatment. CONCLUSIONS: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors.
Authors: Timothy P Moran; Joseph E Burgents; Brian Long; Ivana Ferrer; Elizabeth M Jaffee; Roland M Tisch; Robert E Johnston; Jonathan S Serody Journal: Vaccine Date: 2007-07-17 Impact factor: 3.641
Authors: Peter J Attayek; Sally A Hunsucker; Christopher E Sims; Nancy L Allbritton; Paul M Armistead Journal: Integr Biol (Camb) Date: 2016-12-05 Impact factor: 2.192
Authors: Brian J Morrison; Chris W Schmidt; Sunil R Lakhani; Brent A Reynolds; J Alejandro Lopez Journal: Breast Cancer Res Date: 2008-07-22 Impact factor: 6.466
Authors: Karen V Swanson; Robert D Junkins; Cathryn J Kurkjian; Elizabeth Holley-Guthrie; Avani A Pendse; Rachid El Morabiti; Alex Petrucelli; Glen N Barber; Chris A Benedict; Jenny P-Y Ting Journal: J Exp Med Date: 2017-10-13 Impact factor: 14.307
Authors: Michael A Morse; Amy Hobeika; Takuya Osada; Donna Niedzwiecki; Paul Kelly Marcom; Kimberly L Blackwell; Carey Anders; Gayathri R Devi; H Kim Lyerly; Timothy M Clay Journal: J Transl Med Date: 2007-09-06 Impact factor: 5.531